Celcuity Inc. has unveiled a corporate presentation focusing on the potential of treating cancers involving the PI3K/AKT/mTOR $(PAM)$ pathway. The presentation highlights Gedatolisib's unique mechanism of action and pharmacokinetic profile, showcasing its potency and tolerability as a PAM inhibitor. Noteworthy data from trials indicate promising outcomes for patients with HR+/HER2- advanced breast cancer, with median progression-free survival (mPFS) of 48 months in first-line and 12.9 months in second-line patients. The company is advancing Phase 3 studies for these patient groups, with enrollment for first-line patients expected to commence in the second quarter of 2025. Additionally, Celcuity is exploring gedatolisib's potential for prostate cancer treatment, citing scientific parallels between breast and prostate cancer. The presentation emphasizes the substantial untapped opportunity within the PAM pathway, affecting a large patient population across the US, EU, and Japan. You can access the full presentation through the link below.